Please provide your email address to receive an email when new articles are posted on . 92%, 62% and 60% of subjects were satisfied with their outcomes at months 1, 6 and 12 post-treatment, ...
ZUG, Switzerland--(BUSINESS WIRE)--Galderma today announced new phase III data from the READY-4 clinical trial, demonstrating the long-term safety of RelabotulinumtoxinA (Relfydess â„¢) for frown lines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results